高级检索
当前位置: 首页 > 详情页

Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China [2]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China [3]Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China [4]Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, 610041, PR China
出处:
ISSN:

关键词: Antitumor immunity Gasdermin Head and neck squamous cell carcinoma Prognosis Pyroptosis

摘要:
In several studies of head and neck squamous cell carcinoma (HNSC), the regulation of tumorigenesis and therapeutic sensitivity by pyroptosis has been observed. However, a systematic analysis of gasdermin family members (GSDMs, including GSDMA/B/C/D/E and PJVK), which are deterministic executors of pyroptosis, has not yet been reported in HNSC.We performed comprehensive analyses of the expression profile, prognostic value, regulatory network, and immune infiltration modulation of GSDMs in HNSC on the basis of a computational approach and bioinformatic analysis of publicly available datasets.A total of 18.65 % (94/504) of HNSC patients harbored GSDM alterations, with the most dominant type being amplification. Compared with those in normal tissues, the mRNA and protein levels of GSDMs, especially GSDMD/E, were commonly elevated in HNSC (P < 0.05). Additionally, the expression of GSDMs differed significantly between the clinicopathological subgroups of HNSC patients. Overall survival of HNSC patients benefited from increased GSDMC expression (HR = 0.67, P = 0.0053) and decreased GSDME expression (HR = 1.42, P = 0.0140). Regulatory network analysis revealed several essential biological processes associated with GSDMs, including positive regulation of cytokine production involved in the immune response. Notably, almost all infiltrating immune cells and immune checkpoints were negatively correlated with GSDMA/C/E expression and positively related to GSDMB/D and PJVK expression.We indicated the potential role of GSDMs (especially GSDME) in HNSC pathogenesis, progression and response to immunotherapy, providing important evidence for further prospective studies and molecular mechanism exploration.© 2024 The Authors.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 综合性期刊
小类 | 4 区 综合性期刊
最新[2025]版:
大类 | 4 区 综合性期刊
小类 | 4 区 综合性期刊
第一作者:
第一作者机构: [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China [4]Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, 610041, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:55618 今日访问量:0 总访问量:4702 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号